Comparative in vitro activity of antimycotic agents against pathogenic vaginal yeast isolates
- PMID: 7983571
Comparative in vitro activity of antimycotic agents against pathogenic vaginal yeast isolates
Abstract
Although numerous antimycotic agents are available for the treatment of yeast vaginitis there is little comparative data on the in vitro activity of these drugs. In the present two-part study, in vitro macro-broth dilution sensitivity tests were performed on a total of 377 clinical vaginal yeast isolates of nine different species. Antimycotics surveyed included amphotericin B, 5-fluorocytosine and eight azole derivatives. Results show that all vaginal Candida albicans isolates were uniformly sensitive at low concentration to all 10 antimycotics tested. However, non-albicans species, especially Candida glabrata and Saccharomyces cerevisiae, manifested several-fold increases in minimal inhibitory concentrations to all azoles tested except butoconazole. In particular, the in vitro potency of fluconazole and terconazole against species other than C. albicans was relatively poor, whereas the drugs demonstrating the best activity were itraconazole, butoconazole and saperconazole. Susceptibility testing of vaginal C. albicans isolates is not routinely indicated, even in patients with recurrent vaginitis and should be reserved for selected organisms, especially non-albicans species, in patients with clinical failure only.
Similar articles
-
[Vaginal candidiasis: etiology and sensitivity profile to antifungal agents in clinical use].Rev Argent Microbiol. 2001 Oct-Dec;33(4):217-22. Rev Argent Microbiol. 2001. PMID: 11833253 Spanish.
-
Torulopsis glabrata vaginitis: clinical aspects and susceptibility to antifungal agents.Obstet Gynecol. 1990 Oct;76(4):651-5. Obstet Gynecol. 1990. PMID: 2216197
-
In vitro activities of voriconazole (UK-109, 496), fluconazole, itraconazole and amphotericin B against 132 non-albicans bloodstream yeast isolates (CANARI study).Mycoses. 2004 Jun;47(5-6):177-83. doi: 10.1111/j.1439-0507.2004.00971.x. Mycoses. 2004. PMID: 15189180
-
[The activity of systemic antimycotic drug combinations].Rev Esp Quimioter. 2001 Mar;14(1):30-9. Rev Esp Quimioter. 2001. PMID: 11376347 Review. Spanish.
-
[Fungal diseases of vulva and vagina caused by Candida species].Med Monatsschr Pharm. 2010 Sep;33(9):324-33; quiz 335-6. Med Monatsschr Pharm. 2010. PMID: 21192442 Review. German.
Cited by
-
Antimicrobial Resistance in Vulvovaginitis.Curr Infect Dis Rep. 2001 Dec;3(6):546-549. doi: 10.1007/s11908-001-0093-5. Curr Infect Dis Rep. 2001. PMID: 11722813
-
Fluconazole. An update of its antimicrobial activity, pharmacokinetic properties, and therapeutic use in vaginal candidiasis.Drugs. 1995 Jun;49(6):984-1006. doi: 10.2165/00003495-199549060-00009. Drugs. 1995. PMID: 7641607 Review.
-
Effect of butoconazole nitrate 2% vaginal cream and miconazole nitrate 2% vaginal cream treatments in patients with vulvovaginal candidiasis.Infect Dis Obstet Gynecol. 1996;4(6):323-8. doi: 10.1155/S1064744996000658. Infect Dis Obstet Gynecol. 1996. PMID: 18476119 Free PMC article.
-
Pathogenesis of Recurrent Vulvovaginal Candidiasis.Curr Infect Dis Rep. 2002 Dec;4(6):514-519. doi: 10.1007/s11908-002-0038-7. Curr Infect Dis Rep. 2002. PMID: 12433327
-
Azole resistance in Candida.Eur J Clin Microbiol Infect Dis. 1997 Apr;16(4):261-80. doi: 10.1007/BF01695630. Eur J Clin Microbiol Infect Dis. 1997. PMID: 9177959 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical